A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2023-07-29
AEs
3
Serious
2
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-02 (study day 28); relationship: not assessed; serious criteria: life-threatening
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-11-24 (study day 111); relationship: not assessed
severe
serious
assessed
Grade 4 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-01-16 (study day 164); relationship: N; serious criteria: life-threatening
Data queries
No data queries.